YM BioSciences :: Products :: CYT387

Indication	Phase I	Phase II	Phase III	Publications
Myelofibrosis [CYT387 (oral) monotherapy] Study Design: dose-escalation with cohort expansion at biologically active doses Primary Endpoints: dose-limiting toxicities, maximum tolerated dose, safety and tolerability Secondary Endpoints: effect on spleen size, hematological symptoms, quality of life, markers of aberrant JAK2 activity in blood # Patients: 30-60 (enrollment ongoing) Trial Location: Australia Lead Sponsor: YM BioSciences Australia

completed study

ongoing study

multi-phase study